↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: Anaplastic Lymphoma Kinase Gene (ALK)

FDA Approves Crizotinib [Xalkori] with Companion Diagnostic Test for Non-Small Cell Lung Cancers (NSCLC) Positive for the Anaplastic Lymphoma Kinase (ALK) Gene

By Joseph Gut - thasso Posted on August 28, 2011 Posted in New Drug Approval, Personalized Medicine Tagged with Anaplastic Lymphoma Kinase Gene (ALK), Companion Test, Crizotinib [Xalkori], Non-Small Cell Lung Cancers (NSCLC), Personalized Medicine, Thasso Post, Theragenomic Medicine

August 26, 2011 – Today, the  American Food and Drug Administration (FDA) has approved Crizotinib [Xalkori] to treat the patient subgroup with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) whos cancers express (i.e., test positive for the …

FDA Approves Crizotinib [Xalkori] with Companion Diagnostic Test for Non-Small Cell Lung Cancers (NSCLC) Positive for the Anaplastic Lymphoma Kinase (ALK) Gene Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme